title: Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors.
abstract: Clear and unambiguous associations have been established between therapeutic exposures and specific complications. However, considerable interindividual variability is observed in the risk of developing an outcome for a given therapeutic exposure. Genetic predisposition and especially its interaction with therapeutic exposures can potentially exacerbate the toxic effect of treatment on normal tissues and organ systems, and can possibly explain the interindividual variability. This article provides a brief overview of the current knowledge about the role of genomic variation in the development of therapy-related complications. Relatively common outcomes with strong associations with therapeutic exposures, including cardiomyopathy, obesity, osteonecrosis, ototoxicity, and subsequent malignancies are discussed here. To develop a deeper understanding of the molecular underpinnings of therapy-related complications, comprehensive and near-complete collection of clinically annotated samples is critical. Methodologic issues such as study design, definition of the endpoints or phenotypes, identification of appropriate and adequately sized study population together with a reliable plan for collecting and maintaining high-quality DNA, and selection of an appropriate approach or platform for genotyping are also discussed. Understanding the etiopathogenetic pathways that lead to the morbidity is critical to developing targeted prevention and intervention strategies, optimizing risk-based health care of cancer survivors, thus minimizing chronic morbidities and improving quality of life.
authors: Department of Population Sciences, City of Hope, Duarte, CA 91010-3000, USA. sbhatia@coh.org
authors: Smita
authors: S
authors: Bhatia
mesh_terms: D015897:Comorbidity / Q000639:trends*; D020022:Genetic Predisposition to Disease; D006801:Humans; D009369:Neoplasms / Q000453:epidemiology / Q000235:genetics / Q000401:mortality* / Q000628:therapy*; D011379:Prognosis; D015996:Survival Rate; D017741:Survivors